Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2021 on November 9, 2021, before market opens. Following this, a conference call is scheduled at 8:30 AM ET to discuss the results. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering products like Motiva Implants®. Since 2010, over 1.6 million implants have been distributed worldwide in over 80 countries. The company is focused on regulatory approvals for its innovative products.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) launched JOY™, a new patient-centric breast aesthetics program featuring the latest Motiva Ergonomix2® implants. JOY offers comprehensive support, including the Motiva Woman’s Choice Program™, which provides financial assistance for implant removal, and surgeon options for reverse procedures at no additional cost. Announced at the 6th World Symposium on Ergonomic Implants in Italy, JOY aims to enhance the experience for women undergoing breast surgery by combining advanced implant technology with specialized surgeon training.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its support for Breast Cancer Awareness Month in October, focusing on improving access to breast reconstruction. The company will implement the Pink is for Power program in Brazil, providing 200 women with reconstruction surgeries. Key events planned include the Motiva Breast Health Day in Barcelona and the Rosé for Reconstruction event in Italy. With the recent launch of their Motiva Flora tissue expander, Establishment Labs aims to enhance clinical outcomes for breast cancer patients.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) officially launched its Motiva Flora® tissue expander in Europe during a symposium at the London Breast Meeting on September 2, 2021. This RFID-enabled device aims to enhance post-mastectomy reconstruction, improving patient comfort through advanced biocompatibility and MRI imaging capabilities. CEO Juan José Chacón-Quirós highlighted the significance of Flora in capturing a substantial market share in breast reconstruction, projecting improved outcomes for women. Motiva Flora is not yet approved for distribution in the U.S.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva Flora®, a new tissue expander in Europe and CE Mark countries, set for September 2, 2021. This innovative product features patented SmoothSilk® surface technology and RFID-enabled ports, aiming to enhance imaging and patient outcomes. The event will include presentations from medical professionals and discussion on commercialization plans. Currently, Motiva Flora is not approved for distribution in the U.S.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced participation in the UBS Genomics 2.0 and MedTech Innovations Summit from August 10-12, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will address attendees on August 12 at 8:00 am ET. A live webcast of their presentation will be available on the company's investor relations website, along with an archived version post-event. Establishment Labs specializes in women's health, notably breast aesthetics and reconstruction, marketing over 1.6 million Motiva Implants® worldwide since 2010.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported a second-quarter revenue of $32.0 million, up 205% year-over-year, achieving a quarterly record. The company raised its 2021 revenue guidance to $122 million to $126 million, a 44% to 49% increase from 2020. Operating expenses rose to $26.1 million, up 55% from the previous year, contributing to a net loss of $5.3 million. The company maintains a cash balance of $76.8 million. Additionally, notable advancements include the publication of a study on Motiva SmoothSilk implants demonstrating superior biocompatibility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced the publication of its 2020 Corporate Social Responsibility annual review, marking the third anniversary of its NASDAQ listing. CEO Juan José Chacón-Quirós emphasized the company’s commitment to sustainability and governance, alongside financial goals. Key topics included the elevation of Women’s Health as a material focus, the achievement of carbon-neutral certifications, advocacy for women’s health, and highlights of its financial performance. The report aims to align with the 2030 UN Sustainable Development Goals and benchmark against industry peers.
Establishment Labs Holdings (NASDAQ: ESTA) will release its financial results for Q2 2021 on July 29, 2021, prior to market open. A conference call is scheduled for 8:30 am ET the same day to discuss these results. The company specializes in women's health, particularly in breast aesthetics, and offers Motiva Implants®, which are available in over 80 countries. Established in 2018, they received FDA approval for a clinical trial in the U.S. for these implants.